The global veterinary anti-infective market has established a strong position in 2024, with estimated revenue of USD 5.03 billion. This reflects expanding demand for treatments to prevent and control infectious diseases in both livestock and companion animals. Growing concerns over foodborne and zoonotic diseases, increasing pet ownership, and higher investments in animal health infrastructure are among the factors driving this value.
Anti-infective products-including antimicrobial, antiviral, antifungal, and antiparasitic agents-have become central to veterinary medicine, particularly as concerns grow about animal welfare, livestock productivity, and public health.
Full Market Report Available for Delivery. For Purchase or Customization, Please Request Here: https://www.factmr.com/connectus/sample?flag=S&rep_id=10182
From 2024 through 2034, the veterinary anti-infective market is projected to grow steadily to USD 7.47 billion. This forecast is underpinned by moderate but reliable growth trends, as demand from animal healthcare continues to rise in farms, clinics, and companion animal settings.
With more focus being placed on preventing disease rather than only treating outbreaks, veterinary service providers are expected to increase adoption of preventive anti-infectives. Livestock producers are also likely to increase usage as part of biosecurity, hygiene, and food safety measures, while pet care industries will continue pushing the market through increased veterinary visits and improved access to treatment.
Veterinary Anti-Infective Market Growing at ~4% CAGR (2024-2034):
Over the ten-year period, the market is forecasted to expand at a compound annual growth rate of about 4%. While this rate is not extremely high, it reflects stable, dependable growth in a regulated environment. The moderate CAGR is influenced by some headwinds including regulatory scrutiny over antimicrobial resistance, the challenges in developing new anti-infective agents, and cost pressures on producers. However, the drivers-rising animal disease incidence, growing pet owner expectations, and livestock production intensification-provide sufficient momentum for consistent market expansion.
Segmentation and Regional Dynamics:
Within the veterinary anti-infective market, livestock animals contribute the greater share of demand compared to companion animals. The need to protect large herd populations and maintain productivity in meat, dairy, and other animal-derived food sectors drives this dominance. The market also segments by classes of agents: antimicrobial agents lead in share, followed by antiviral, antifungal, and antiparasitic agents. Modes of administration include oral, parenteral, and topical routes, with delivery channels involving veterinary hospitals, clinics, and pharmacies.
Regionally, North America holds a significant proportion of the global market, benefiting from established veterinary healthcare infrastructure, higher per-animal healthcare spending, and stronger awareness of pet health among consumers. Latin America is another notable region, with Brazil representing a major portion of demand due to its large livestock population and increasing regulations for veterinary care. Asia-Pacific is expected to contribute increased growth as livestock farming expands, pet adoption rises, and veterinary services become more accessible in emerging economies.
Key Growth Drivers:
Several interrelated factors are propelling growth in the veterinary anti-infective market. First, the increasing prevalence of zoonotic diseases and concerns about food safety compel livestock producers and governments to invest in anti-infective treatments. Second, the pet animal sector is growing globally, and with it the demand for veterinary care and associated medicaments for companion animals suffering infections.
Third, improvements in veterinary diagnostics, research and development, and regulatory support are improving disease detection and treatment, allowing anti-infectives to be used more effectively and responsibly. Fourth, rising awareness among pet owners and livestock producers about animal health, welfare, and the risks to human health from untreated animal infections is driving more proactive care and treatment.
Recent Developments:
In recent years, the market has seen several developments aimed at improving both supply and responsible use of veterinary anti-infectives. Regulatory authorities are imposing stricter guidelines around antimicrobial resistance, pushing companies and veterinary practices to ensure prudent use of antibiotics and similar agents. Some manufacturers are exploring newer formulations or delivery systems that allow more targeted activity, longer half-lives, or easier administration to reduce treatment burden.
Pet care brands and veterinary pharmaceutical firms are also increasingly focusing on companion animals with specialized products tailored for common pet infections. In livestock, there has been greater emphasis on preventive measures such as improved hygiene, vaccines, and biosecurity to reduce dependency on therapeutic anti-infectives. Additionally, efforts are underway in many regions to expand veterinary healthcare access, especially in rural or underserved areas, which should increase consumption of anti-infective products as awareness and ability to treat diseases improve.
Key Players Insights:
The veterinary anti-infective market is populated by a mix of global giants and regional firms. Major players actively competing include Neogen Corporation, Phibro Animal Health, Sanofi's animal health divisions, Vetoquinol S.A., Virbac S.A., Zoetis, Inc., Boehringer Ingelheim, Ceva Santé Animale, Indian Immunologicals, Intas Pharmaceuticals, Norbrook Laboratories, Zydus Animal Health, and other manufacturers in animal health.
These companies differentiate themselves through research in improved anti-infective agents (for example, better spectrum of activity, safer side-effect profiles), investment in regulatory approvals, expansion into emerging markets, and development of products for both livestock and companion animals. Some of them are also focusing on formulations that reduce the number of doses needed or that combine prevention and treatment in more efficient ways. The ability to navigate regulatory environments, ensure product quality, and respond to antimicrobial resistance concerns is becoming a competitive advantage in the landscape.
Browse Full Report: https://www.factmr.com/report/veterinary-anti-infective-market
Future Outlook:
The outlook for the veterinary anti-infective market through 2034 remains cautiously optimistic. Despite challenges such as antimicrobial resistance, regulatory constraints, and competition from generic alternatives, the market is expected to benefit from rising animal disease incidence, increasing pet population, improvements in veterinary healthcare access, and growing importance of food safety and zoonotic disease control.
As veterinary practice becomes more preventive and diagnostic tools improve, demand may shift toward anti-infective agents used in early intervention, combined therapies, and localized or targeted treatments. Geographic growth is likely to be strongest in regions with expanding livestock farming, rising disposable incomes, and improving veterinary infrastructure-Asia-Pacific, Latin America, and parts of Africa. By 2034, with projected revenue of USD 7.47 billion and a growth rate around 4% CAGR, the veterinary anti-infective market is poised to play a major role in promoting animal welfare, protecting public health, and ensuring sustainable livestock production globally.
Comments
0 comment